- |||||||||| Ozarelix (D-63153) / Spectrum Pharma, Firmagon (degarelix) / Astellas, Ferring, Cetrotide (cetrorelix) / EMD Serono
Journal: Aggregation Behavior of Structurally Similar Therapeutic Peptides Investigated by H NMR and All-Atom Molecular Dynamics Simulations. (Pubmed Central) - Apr 12, 2022 The AA-MD simulations also provided molecular-level insights into aggregation dynamics, aggregation pathways, and the influence of different structural elements on peptide aggregation propensity and intermolecular interactions within the aggregates. Taken together, the findings from this study illustrate that H NMR and AA-MD simulations can be useful, complementary tools in early evaluation of aggregation propensity and formulation development for peptide drugs.
- |||||||||| Firmagon (degarelix) / Astellas, Ferring, Cetrotide (cetrorelix) / EMD Serono
Trial completion date, Trial primary completion date: Dysregulation of FSH in Obesity: Functional and Statistical Analysis (clinicaltrials.gov) - Apr 7, 2022 P=N/A, N=99, Completed, Taken together, the findings from this study illustrate that H NMR and AA-MD simulations can be useful, complementary tools in early evaluation of aggregation propensity and formulation development for peptide drugs. Trial completion date: Mar 2021 --> Jun 2021 | Trial primary completion date: Mar 2021 --> Jun 2021
- |||||||||| Cetrotide (cetrorelix) / EMD Serono
Preclinical, Journal: Bioluminescent imaging in induced mouse models of endometriosis reveals differences in four model variations. (Pubmed Central) - Apr 1, 2022 We compared longitudinal bioluminescence and histology of lesions, sensory behaviour of mice with induced endometriosis and the impact of the gonadotropin-releasing hormone antagonist Cetrorelix on lesion regression and sensory behaviour...Collectively, our results demonstrate key differences in the progression of the 'disease' across different mouse models of endometriosis. We propose that validation and testing in multiple models, each of which may be representative of the different subtypes / heterogeneity observed in women should become a standard approach to discovery science in the field of endometriosis.
- |||||||||| Utrogestan (progesterone) / Besins Healthcare
Trial completion date, Trial primary completion date: Prog_STIM: Micronized Progesterone vs Gonadotropin-releasing Hormone (GnRH) Antagonist in Freeze-all IVF Cycles. (clinicaltrials.gov) - Mar 31, 2022 P=N/A, N=44, Recruiting, We propose that validation and testing in multiple models, each of which may be representative of the different subtypes / heterogeneity observed in women should become a standard approach to discovery science in the field of endometriosis. Trial completion date: Jan 2022 --> Jan 2023 | Trial primary completion date: Sep 2021 --> Sep 2022
- |||||||||| letrozole / Generic mfg.
Trial completion date, Trial primary completion date: Letrozole in Stimulated IVF Cycles (clinicaltrials.gov) - Mar 31, 2022 P3, N=900, Recruiting, Trial completion date: Jan 2022 --> Jan 2023 | Trial primary completion date: Sep 2021 --> Sep 2022 Trial completion date: Dec 2022 --> Oct 2023 | Trial primary completion date: Dec 2021 --> Apr 2022
- |||||||||| Cetrotide (cetrorelix) / EMD Serono
Clinical, Journal: GnRH Antagonist Protocol With Cessation of Cetrorelix on Trigger Day Improves Embryological Outcomes for Patients With Sufficient Ovarian Reserve. (Pubmed Central) - Feb 19, 2022 Furthermore, for patients with 1.1 ≤ AMH ≤ 4.7 ng/ml, all embryological outcomes were significantly higher in Group B compared with Group A. For patients with AMH > 4.7 ng/ml, the number of oocytes retrieved, fertilization rate (2PN) of IVF cycles and proportion of day 3 good quality embryos were all significantly higher in Group B. For patients with age 35 years or AMH < 1.1 ng/ml. GnRH-ant protocol with cessation of cetrorelix on trigger day improved embryological outcomes for young patients or patients with sufficient ovarian reserve, and was effective at preventing preovulation.
- |||||||||| Trial completion, Trial completion date, Trial primary completion date: Progestin Primed Double Stimulation Protocol Versus Flexible GnRH Antagonist Protocol in Poor Responders (clinicaltrials.gov) - Feb 17, 2022
P3, N=90, Completed, Eventually, the proposed method was used for the extraction and quantification of target therapeutic peptides in plasma and urine samples, and satisfactory relative recoveries were achieved in the range of 90.6-110.3%. Not yet recruiting --> Completed | Trial completion date: Dec 2021 --> Sep 2021 | Trial primary completion date: Sep 2021 --> Mar 2021
- |||||||||| Orgovyx (relugolix) / Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Dainippon
Journal: A novel orally active gonadotropin-releasing hormone antagonist, relugolix, is a potential substitute for injectable GnRH antagonists in controlled ovarian stimulation in assisted reproductive technology. (Pubmed Central) - Dec 24, 2021 The number of oocytes collected, fertilization rates, and pregnancy rates (R; 47.1% vs C; 45.8%) did not differ between the two groups. An orally active GnRH Ant, relugolix, when used in controlled ovarian stimulation for ART, showed comparable clinical outcomes with cetrorelix.
- |||||||||| Cetrotide (cetrorelix) / EMD Serono
Journal: Neuromodulatory effects of GnRH on the caudal neurosecretory Dahlgren cells in female olive flounder. (Pubmed Central) - Nov 29, 2021 A positive correlation was observed between the UII and GnRH-R mRNA levels in CNSS or gonadosomatic index (GSI) during the breeding season. These findings are the first demonstration of the ability of GnRH acts as a modulator within the CNSS and add to our understanding of the physiological role of the CNSS in reproduction and seasonal adaptation.
- |||||||||| Cetrotide (cetrorelix) / EMD Serono
Preclinical, Journal: Neuromodulatory effect of GnRH from coeliac ganglion on luteal regression in the late pregnant rat. (Pubmed Central) - Nov 29, 2021 Cetrorelix (CTX), a GnRH receptor antagonist, was added into the ganglionic compartment while the control systems were untreated...In turn, CTX in CG caused an increase in ovarian progesterone release...CTX in CG decreased the ovarian noradrenaline release. The present study provides evidence that GnRH from CG may trigger neuronal signals that promote the luteal regression in late pregnancy by affecting the release of NO and noradrenaline in the ovary.
- |||||||||| Cetrotide (cetrorelix) / EMD Serono
Clinical, Journal: Ovarian Filariasis: Diagnosis by detection of microfilariae in follicular fluid, a case report. (Pubmed Central) - Nov 25, 2021 Antagonist protocol is one of the standard protocols used for controlled ovarian hyperstimulation as a part of the IVF/ICSI(in-vitro fertilization / intracytoplasmic sperm injection) procedure where GnRH antagonist (cetrorelix) is used to suppress the endogenous LH surge...The patient was treated with Diethylcarbamazine citrate. There are so many reports about scrotal Filariasis, but rare literature quotes ovarian Filariasis.
- |||||||||| Cetrotide (cetrorelix) / EMD Serono
Trial completion date, Trial primary completion date: The LUTEAL Trial: Luteal Stimulation vs. Estrogen Priming Protocol (clinicaltrials.gov) - Nov 18, 2021 P=N/A, N=142, Recruiting, There are so many reports about scrotal Filariasis, but rare literature quotes ovarian Filariasis. Trial completion date: Mar 2022 --> Jun 2022 | Trial primary completion date: Jul 2021 --> Jun 2022
- |||||||||| Cetrotide (cetrorelix) / EMD Serono
Journal: Kisspeptin induces LH release and ovulation in an induced ovulator. (Pubmed Central) - Sep 12, 2021 Llamas pretreated with saline had elevated plasma LH concentrations and ovulated (6/6) whereas llamas pretreated with cetrorelix did not (0/6)...We found no colocalization between kisspeptin and NGF receptors by double immunofluorescence. Functional and morphological findings support the concept that kisspeptin is a mediator of the LH secretory pathway in llamas; however, the role of kisspeptins in the NGF ovulation-inducing pathway in camelids remains unclear since NGF receptors were not detected in kisspeptin neurons in the hypothalamus.
- |||||||||| Cetrotide (cetrorelix) / EMD Serono
Preclinical, Journal: Effect of Cetrorelix administration on ovarian stimulation in aged mice. (Pubmed Central) - Jul 28, 2021 It is concluded that Cetrorelix improved the effect of superovulation in aged mice without reducing oocyte quality. This procedure will contribute to animal welfare by extending the effective utilization of aged female breeding mice.
- |||||||||| Cetrotide (cetrorelix) / EMD Serono
Preclinical, Journal: Hepatic in vitro metabolism of peptides; Comparison of human liver S9, hepatocytes and Upcyte hepatocytes with cyclosporine A, leuprorelin, desmopressin and cetrorelix as model compounds. (Pubmed Central) - Jun 22, 2021 For leuprorelin and cetrorelix, the metabolites that showed NADPH dependency with liver S9, were not detected with hepatocytes, even though for leuprorelin these reactions played a major role in liver S9. The hydrolytic metabolic reactions were very similar between liver S9 and hepatocytes, i.e. the metabolite profiles in hepatocytes matched better with liver S9 profiles without NADPH, which may be caused by cell uptake rate limitation with hepatocytes, or then hydrolytic processes are more stressed in peptide metabolism with hepatocytes, in comparison to CYP-mediated processes.
- |||||||||| Cetrotide (cetrorelix) / EMD Serono
Clinical, Review, Journal: Controlled ovarian stimulation therapy as a potential risk for the development and progression of renal cell carcinomas: A case report and literature review. (Pubmed Central) - Jun 8, 2021 A 35-year-old woman received fertility stimulation treatment with follitropin alfa 900 units, human chorionic gonadotropic hormone 5,000 units, injectable leuprolide 1 mg/0.2 ml and cetrotide 0.25 mg...To the best of our knowledge, this was the first time that a case of ovarian stimulation therapy was associated with the development of RCC. This case raises concerns about the potential oncogenic effect of controlled ovarian stimulation therapy in RCC promotion, suggesting a need for systematic research to clarify the clinical significance of existing pre-clinical data.
- |||||||||| Cetrotide (cetrorelix) / EMD Serono
Trial completion, Preclinical: NATOS: NATural Ovarian Stimulation (clinicaltrials.gov) - Apr 30, 2021 P4, N=129, Completed, This case raises concerns about the potential oncogenic effect of controlled ovarian stimulation therapy in RCC promotion, suggesting a need for systematic research to clarify the clinical significance of existing pre-clinical data. Active, not recruiting --> Completed
- |||||||||| letrozole / Generic mfg.
Trial completion date, Trial primary completion date: Letrozole in Stimulated IVF Cycles (clinicaltrials.gov) - Apr 29, 2021 P3, N=900, Recruiting, Active, not recruiting --> Completed Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2020 --> Dec 2021
- |||||||||| Cetrotide (cetrorelix) / EMD Serono
Journal: Gonadotropin-releasing hormone-independent effects of recombinant vertebrate ancient long opsin in the goldfish Carassius auratus reveal alternative reproduction pathways. (Pubmed Central) - Apr 13, 2021 Goldfish were injected with recombinant VAL-opsin protein (0.5 μg/g body mass) and/or the GnRH antagonist cetrorelix (0.5 μg/fish), and changes in the mRNA expression levels of genes associated with goldfish reproduction were measured by quantitative polymerase chain reaction, including those involved in the hypothalamus-pituitary-gonad (HPG) axis, VAL-opsin, GnRH, the gonadotropins (GTHs) luteinizing hormone and follicle-stimulating hormone, and estrogen receptor (ER)...These results indicate that green LED is an effective light source to promote the expression of sex hormones in fish. Moreover, VAL-opsin not only affects activity of the HPG axis but also appears to act on the pituitary gland directly to stimulate a new sexual maturation pathway that promotes the secretion of GTHs independent of GnRH.
- |||||||||| Cetrotide (cetrorelix) / EMD Serono
Journal: Appraisal of different levels of soybean meal in diets on growth, digestive enzyme activity, antioxidation, and gut histology of tilapia (Oreochromis niloticus). (Pubmed Central) - Apr 13, 2021 The SBM0 contained 100% FM, followed by 25% (SBM25), 50% (SBM50), 75% (SBM75), and 100% (SBM100)...The antioxidant enzymes including superoxide dismutase and catalase of the liver were significantly (P < 0.01) higher in fish fed SBM100 compared with SBM0. These results suggest that the replacement of FM up to 75% with SBM could be possible considering the growth performances, gut health, and activities of digestive enzymes and antioxidant enzymes in O. niloticus.
- |||||||||| Orgalutran (ganirelix acetate) / Organon, Cetrotide (cetrorelix) / EMD Serono
Trial completion date, Trial primary completion date: Live Birth Rate Between PPOS and GnRH Antagonist Protocol in Patients With Anticipated High Ovarian Response (clinicaltrials.gov) - Mar 18, 2021 P3, N=784, Recruiting, Influence of various deposition parameters was studied to obtain the optimized conditions for the growth of a thin film based EO modulator.Surface morphology of the SBN60 and SBN75 thin film after deposition using PLD technique Trial completion date: Oct 2022 --> Oct 2024 | Trial primary completion date: Jul 2022 --> Jul 2023
|